A Look At Sihuan Pharmaceutical Holdings Group (SEHK:460) Valuation After New Earnings Guidance And Segment Growth

Simply Wall St.02-19

AdvertisementGuidance-driven spotlight on Sihuan Pharmaceutical Holdings Group Sihuan Pharmaceutical Holdings Group (SEHK:460) caught investor attention after issuing unaudited 2025 earnings guidance,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612405689?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-02-19 15:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612405689","market":"sg","top_or_hot":-1,"title":"A Look At Sihuan Pharmaceutical Holdings Group (SEHK:460) Valuation After New Earnings Guidance And Segment Growth","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementGuidance-driven spotlight on Sihuan Pharmaceutical Holdings Group Sihuan Pharmaceutical Holdings Group (SEHK:460) caught investor attention after issuing unaudited 2025 earnings guidance,...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/a-look-at-sihuan-pharmaceutical-holdings-group-sehk460-valua\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Sihuan Pharmaceutical Holdings Group (SEHK:460) Valuation After New Earnings Guidance And Segment Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Sihuan Pharmaceutical Holdings Group (SEHK:460) Valuation After New Earnings Guidance And Segment Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-19 15:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/a-look-at-sihuan-pharmaceutical-holdings-group-sehk460-valua><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementGuidance-driven spotlight on Sihuan Pharmaceutical Holdings Group Sihuan Pharmaceutical Holdings Group (SEHK:460) caught investor attention after issuing unaudited 2025 earnings guidance,...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/a-look-at-sihuan-pharmaceutical-holdings-group-sehk460-valua\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/a-look-at-sihuan-pharmaceutical-holdings-group-sehk460-valua","article_id":"2612405689","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/a-look-at-sihuan-pharmaceutical-holdings-group-sehk460-valua","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612405689","pubTimestamp":1771486935,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Guidance-driven spotlight on Sihuan Pharmaceutical Holdings Group\nSihuan Pharmaceutical Holdings Group (SEHK:460) caught investor attention after issuing unaudited 2025 earnings guidance, indicating at least RMB 2,500 million in revenue and RMB 150 million in net profit for the year.\nSee our latest analysis for Sihuan Pharmaceutical Holdings Group.\nThe earnings guidance lands after a strong run in the share price, with a 30 day share price return of 25.19% and a year to date gain of 28.12%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1593":"医美概念股","BK1600":"工业大麻","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","00460":"四环医药"},"translate_title":"新盈利指引和部门增长后四环医药控股集团（SEHK：460）估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9,"DCF":1},"content_text":"AdvertisementGuidance-driven spotlight on Sihuan Pharmaceutical Holdings Group Sihuan Pharmaceutical Holdings Group (SEHK:460) caught investor attention after issuing unaudited 2025 earnings guidance, indicating at least RMB 2,500 million in revenue and RMB 150 million in net profit for the year. See our latest analysis for Sihuan Pharmaceutical Holdings Group. The earnings guidance lands after a strong run in the share price, with a 30 day share price return of 25.19% and a year to date gain of 28.12%. The 1 year total shareholder return of 166.35% signals powerful momentum that contrasts with a weaker 5 year total shareholder return of 13.05%. If this update has you thinking more broadly about healthcare opportunities, it could be a good moment to scan 109 healthcare AI stocks for potential ideas beyond Sihuan Pharmaceutical Holdings Group. With guidance pointing to higher revenue and a swing to net profit after a recent share price surge, the key question now is whether Sihuan Pharmaceutical Holdings Group is still undervalued or if the market is already pricing in future growth. Preferred price-to-sales of 6.3x: Is it justified? Right now, the key valuation reference point for Sihuan Pharmaceutical Holdings Group is its P/S of 6.3x, which sits well above the Hong Kong pharmaceuticals industry but below the level suggested by our fair ratio work. The P/S ratio compares the company’s market value to its revenue and is often used when earnings are negative, as is the case here. For Sihuan Pharmaceutical Holdings Group, that 6.3x multiple is described as good value against peers on one hand and expensive on the other, so it helps to separate those two comparisons. On a peer comparison basis, Sihuan Pharmaceutical Holdings Group screens as good value versus a peer average P/S of 11.9x. This implies the market assigns a lower revenue multiple to the company than to that broader peer set. Against the estimated fair P/S of 9.2x, the current 6.3x is also framed as good value, hinting at room for the multiple to move closer to that level if the market view shifts. Where the picture changes is versus the Hong Kong pharmaceuticals industry, where the average P/S is 2.8x. In that context, Sihuan Pharmaceutical Holdings Group looks expensive, with its current multiple more than twice the industry level. This suggests investors are already paying a premium relative to the sector even if some comparative and fair ratio work points to upside in the specific company case. Explore the SWS fair ratio for Sihuan Pharmaceutical Holdings Group Result: Price-to-Sales of 6.3x (ABOUT RIGHT) However, you also need to weigh risks such as the current net loss of CN¥80.635 million, as well as any potential disappointment relative to the unaudited 2025 guidance. Find out about the key risks to this Sihuan Pharmaceutical Holdings Group narrative. Another view using the SWS DCF model While the 6.3x P/S ratio can look reasonable when you compare Sihuan Pharmaceutical Holdings Group with peers, our DCF model paints a very different picture. With the share price at HK$1.64 and an estimated future cash flow value of HK$0.11, the model points to a large premium to its intrinsic value. That gap could reflect optimism around future revenue guidance or simply a mismatch between price and cash flow expectations. The key question is which story you think is closer to reality. Look into how the SWS DCF model arrives at its fair value. 460 Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sihuan Pharmaceutical Holdings Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 222 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of signals seems conflicting, consider taking a closer look now and stress test the story against the numbers yourself with 1 key reward Looking for more investment ideas? If you are serious about building a stronger portfolio, do not stop at one stock. Use the screener to spot opportunities others might miss before they move.  Target potential mispricings by checking our 222 high quality undervalued stocks that combine quality fundamentals with attractive entry points. Strengthen your income stream by reviewing 435 dividend fortresses that focus on higher yielding companies with the potential to support regular payouts. Prioritise resilience by scanning 328 resilient stocks with low risk scores that score well on risk, so you can focus attention where the downside looks more controlled.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612405689","isCrawlerRequest":true}